Considerations for Medication for Addiction Treatment in Patients with HIV

Patient name:	
Current HAART regimen:	
Most recent CD4+ count:	Date:
Most recent HIV viral load result:	Date:
HIV provider contact information:	
Points for discussion:	
Treatment for opioid use disorder will not interfere with HIV management	
Treatment selection will be determined by clinical opioid need	
 If naltrexone therapy is planned, key discussion point: No interaction with antiretrovirals 	
 If buprenorphine/naloxone treatment is planned, key discussion points: Buprenorphine/naloxone has a more benign drug interaction profile than methadone Protease inhibitors may increase buprenorphine/naloxone levels; not clinically significant except for: Increases in buprenorphine/naloxone levels with atazanavir and atazanavir/ritonavir associated with sedation and cognitive impairment; may require decreased buprenorphine/naloxone dose for symptoms to disappear Advise patient of possible side effects Non-nucleoside reverse transcriptase inhibitors (NNRTIs) May decrease buprenorphine/naloxone dose Advise patient of possible side effects Notes from patient discussion: 	

CONSIDER SCANNING THIS DOCUMENT INTO THE PATIENT RECORD. MORE INFORMATION IS AVAILABLE IN THE OBAT POLICY AND PROCEDURE MANUAL

This document has been reproduced with permission from Boston Medical Center[©] and is excerpted from: LaBelle, C. T.; Bergeron, L. P.; Wason, K.W.; and Ventura, A. S. Policy and Procedure Manual of the Office Based Addiction Treatment Program for the use of Buprenorphine and Naltrexone Formulations in the Treatment of Substance Use Disorders. Unpublished treatment manual, Boston Medical Center, 2016. This manual or any documents therein are not a substitute for informed medical decision making by an appropriate, licensed provider.